Quest Diagnostics Receivables 2010-2024 | DGX

Quest Diagnostics receivables for the quarter ending December 31, 2024 were $1.376B, a 7.42% increase year-over-year.

  • Quest Diagnostics receivables for 2024 were $1.304B, a 7.77% increase from 2023.
  • Quest Diagnostics receivables for 2023 were $1.21B, a 1.26% increase from 2022.
  • Quest Diagnostics receivables for 2022 were $1.195B, a 16.9% decline from 2021.

Quest Diagnostics Receivables 2010-2024 | DGX

  • Quest Diagnostics receivables for 2024 were $1.304B, a 7.77% increase from 2023.
  • Quest Diagnostics receivables for 2023 were $1.21B, a 1.26% increase from 2022.
  • Quest Diagnostics receivables for 2022 were $1.195B, a 16.9% decline from 2021.
Related Stocks
Company NameMarket
Cap
Fresenius SE (FSNUY)$21.5B
DaVita (DVA)$12.4B
Encompass Health (EHC)$10.2B
Chemed (CHE)$8.4B
Elanco Animal Health (ELAN)$5.6B
Option Care Health (OPCH)$5.5B
RadNet (RDNT)$4.8B
LifeStance Health (LFST)$3.1B
Amedisys (AMED)$3B
Astrana Health (ASTH)$2.2B
Addus HomeCare (ADUS)$2.1B
U.S Physical Therapy (USPH)$1.3B
Aveanna Healthcare Holdings (AVAH)$968M
Pennant (PNTG)$927M
Atai Life Sciences (ATAI)$351M
Bioqual (BIOQ)$54M
Daxor (DXR)$35M
Ontrak (OTRK)$7M
MEDIROM Healthcare Technologies (MRM)$4M
IMAC Holdings (BACK)$1M
Psychemedics (PMD)$0M